NDLI: Predicting drug response of tumors from integrated genomic profiles by deep neural networks

Content Provider	Springer Nature : BioMed Central
Author	Chiu, Yu-Chiao Chen, Hung-I Harry Zhang, Tinghe Zhang, Songyao Gorthi, Aparna Wang, Li-Ju Huang, Yufei Chen, Yidong
Abstract	Background The study of high-throughput genomic profiles from a pharmacogenomics viewpoint has provided unprecedented insights into the oncogenic features modulating drug response. A recent study screened for the response of a thousand human cancer cell lines to a wide collection of anti-cancer drugs and illuminated the link between cellular genotypes and vulnerability. However, due to essential differences between cell lines and tumors, to date the translation into predicting drug response in tumors remains challenging. Recently, advances in deep learning have revolutionized bioinformatics and introduced new techniques to the integration of genomic data. Its application on pharmacogenomics may fill the gap between genomics and drug response and improve the prediction of drug response in tumors. Results We proposed a deep learning model to predict drug response (DeepDR) based on mutation and expression profiles of a cancer cell or a tumor. The model contains three deep neural networks (DNNs), i) a mutation encoder pre-trained using a large pan-cancer dataset (The Cancer Genome Atlas; TCGA) to abstract core representations of high-dimension mutation data, ii) a pre-trained expression encoder, and iii) a drug response predictor network integrating the first two subnetworks. Given a pair of mutation and expression profiles, the model predicts IC50 values of 265 drugs. We trained and tested the model on a dataset of 622 cancer cell lines and achieved an overall prediction performance of mean squared error at 1.96 (log-scale IC50 values). The performance was superior in prediction error or stability than two classical methods (linear regression and support vector machine) and four analog DNN models of DeepDR, including DNNs built without TCGA pre-training, partly replaced by principal components, and built on individual types of input data. We then applied the model to predict drug response of 9059 tumors of 33 cancer types. Using per-cancer and pan-cancer settings, the model predicted both known, including EGFR inhibitors in non-small cell lung cancer and tamoxifen in ER+ breast cancer, and novel drug targets, such as vinorelbine for TTN-mutated tumors. The comprehensive analysis further revealed the molecular mechanisms underlying the resistance to a chemotherapeutic drug docetaxel in a pan-cancer setting and the anti-cancer potential of a novel agent, CX-5461, in treating gliomas and hematopoietic malignancies. Conclusions Here we present, as far as we know, the first DNN model to translate pharmacogenomics features identified from in vitro drug screening to predict the response of tumors. The results covered both well-studied and novel mechanisms of drug resistance and drug targets. Our model and findings improve the prediction of drug response and the identification of novel therapeutic options.
Related Links	https://bmcmedgenomics.biomedcentral.com/counter/pdf/10.1186/s12920-018-0460-9.pdf
Ending Page	155
Page Count	13
Starting Page	143
File Format	HTM / HTML
ISSN	17558794
DOI	10.1186/s12920-018-0460-9
Journal	BMC Medical Genomics
Issue Number	1
Volume Number	12
Language	English
Publisher	BioMed Central
Publisher Date	2019-01-31
Access Restriction	Open
Subject Keyword	Human Genetics Microarrays Gene Expression Deep neural networks Pharmacogenomics Drug response prediction Cancer cell line encyclopedia Genomics of Drug Sensitivity in Cancer The Cancer Genome Atlas
Content Type	Text
Resource Type	Article
Subject	Genetics (clinical) Genetics
Journal Impact Factor	2.1/2023
5-Year Journal Impact Factor	2.5/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Correction to: Predicting drug response of tumors from integrated genomic profiles by deep neural networks

Convolutional neural network models for cancer type prediction based on gene expression

Genomics of drug sensitivity in bladder cancer: an integrated resource for pharmacogenomic analysis in bladder cancer

Unearthing new genomic markers of drug response by improved measurement of discriminative power

A systematic analysis of genomics-based modeling approaches for prediction of drug response to cytotoxic chemotherapies

Predicting drug response of tumors from integrated genomic profiles by deep neural networks

Predict drug sensitivity of cancer cells with pathway activity inference

Network-based drug sensitivity prediction

A deep neural network approach to predicting clinical outcomes of neuroblastoma patients

Predicting drug response of tumors from integrated genomic profiles by deep neural networks

Similar Documents

Correction to: Predicting drug response of tumors from integrated genomic profiles by deep neural networks

Convolutional neural network models for cancer type prediction based on gene expression

Genomics of drug sensitivity in bladder cancer: an integrated resource for pharmacogenomic analysis in bladder cancer

Unearthing new genomic markers of drug response by improved measurement of discriminative power

A systematic analysis of genomics-based modeling approaches for prediction of drug response to cytotoxic chemotherapies

Predicting drug response of tumors from integrated genomic profiles by deep neural networks

Predict drug sensitivity of cancer cells with pathway activity inference

Network-based drug sensitivity prediction

A deep neural network approach to predicting clinical outcomes of neuroblastoma patients

Predicting drug response of tumors from integrated genomic profiles by deep neural networks